Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Col... (nd Phase II human trials using REOLYSIN(...)

HOME >> MEDICINE >> TECHNOLOGY

Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration

Date:2/4/2009

nd Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

About CTRC at UTHSCSA

The CTRC at the UT Health Science Center serves more than 4.4 million people in the high-growth corridor of South and Central Texas, including San Antonio, Austin, Laredo and the Rio Grande Valley. It handles more than 120,000 patient visits each year. The mission of the CTRC at the UT Health Science Center is to promote interdisciplinary research in cancer-related areas of basic science, clinical research, and cancer prevention and control, and to foster the application of the results of that research in the community setting, especially in the South Texas community. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical research studies program in the world. In a Phase I research study, a new agent for cancer is tested in human patients for the first time. Fifteen of the cancer drugs most recently approved by the U.S. Food and Drug Administration underwent development or testing at the IDD.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the CTRC at UTHSCSA-sponsored trials, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the effica
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. VIDEO from Medialink and International HIFU: New Prostate Cancer Procedure Being Tested in US Clinical Trials
2. Society of Gynecologic Oncologists 40th Annual Meeting on Womens Cancer to Include Sessions on Robotics Surgery
3. Winning the War on Cancer: The Critical Role of Radiation Oncology
4. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
5. Research Teams at J. Craig Venter Institute and Ludwig Institute for Cancer Research Uncover New Chromosomal Alterations in Cancer Using Transcriptome Sequencing Approach
6. Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
7. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
8. Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer
9. Chemoembolization Improving as Liver Cancer Treatment
10. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
11. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

Post Your Comments:

(Date:6/19/2013)... , June 19, 2013 Eli Lilly and ... alert about two illegal scams, purportedly using the name ... that are actively targeting the public through postal mail ... have no connection to any foreign lottery organizations and ... by the job-seeking victims of the scam. The activities ...

(Date:6/19/2013)... YORK , June 19, 2013 ... that a new market research report ... Partnerships, Licensing, Investments and ... 2013 in Pharmaceuticals http://www.reportlinker.com/p0925641/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-for-May-2013-in-Pharmaceuticals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking ... Investments and M&A Deals and Trends ...

(Date:6/19/2013)... 2013 Ellen MacArthur Foundation ... tre åren kommer att vara en partner för ... ekonomi. Efter stiftelsens framgångsrika partnerskap med ... kommer Philips att ansluta sig som partner för ... sin egen verksamhet och stödja stiftelsens arbete inom ...

[0] Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests [0] Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals [0] Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi

... NewCardio, Inc., (OTC Bulletin Board: NWCI ... the Company has been invited to present the results ... upcoming conference entitled "Cardiovascular Safety in Drug Development: State-of-the-Art ... (FDA), the Cardiac Safety Research Consortium (CSRC) and the ...

... ICU Medical, Inc. (Nasdaq: ICUI ) ... release of the MicroCLAVE Clear Neutral Displacement Needlefree Connector ... Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas. ... verifying effective flushing of the patient catheter after use ...

Cached Medicine Technology:NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 2 NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 3 NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 4 NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 5 NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 6 ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas 2 ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas 3

NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas

(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...

(Date:6/19/2013)... Amber Roberson with the Robert ... Native Care Health, LLC and Medcase, LLC, became ... (NAHU) new professional development course on the Patient ... education course for agents has been approved in ... education credits from the Missouri Department of Insurance. ...

(Date:6/19/2013)... June 19, 2013 As Januvia ... continue to mount in courts throughout the U.S., Bernstein ... Administration (FDA) recently held a meeting to discuss the ... incretin mimetics. According to a June 12th report ... the makers of Januvia and similar drugs, following a ...

(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...

(Date:6/19/2013)... by researchers at The University of Texas MD Anderson ... remarkable promise for the treatment of relapsed or refractory ... findings of the 18-center Phase 2 study were published ... . Previous interim findings were presented in December 2012 ... and Exposition. , Unprecedented results, fewer side ...

Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2 Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3 Health News:RWI Benefits, LLC Becomes PPACA Certified 2 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3 Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2 Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2

[0] Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent [0] RWI Benefits, LLC Becomes PPACA Certified [0] Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics [0] Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines [0] Ibrutinib continues strong showing against mantle cell lymphoma

... in Comprehensive Report Comparing SSO and ... Healthcare Industry, ANDOVER, Mass., March 19 ... Sign-On (SSO), announced today that it ranked ... comparing SSO and,context management vendors performance. The ...

... in German . , Transport processes in ... on the roads. Molecular motors, which are special protein molecules, ... and transport it along microtubules, which are the roads of ... smaller than trucks and can only move as far as ...

... 19 To develop new strategies to control tuberculosis ... worlds population and kills almost two million people every ... has received an $11.4 million grant from the Bill ... researchers to use new imaging technologies to study TB ...

... 19 Mirion Technologies, the,leading global provider of ... industry, will showcase two new products at the,10th ... from,March 25th - 28th., Mirion,s Health Physics ... Contamination Monitor. The TwoStep Exit monitor is a,new ...

... be at the forefront of fighting cancer thanks to ... Research Foundation (ACRF). , The ACRF funding will ... and Metabolic Medicine (DI), and their partners from the ... tools to help them discover genes linked to cancer. ...

... are more respectful, SAN DIEGO, March 19 Over ... one to three years, find a non-nursing,job, work part-time, or ... by AMN Healthcare, the largest health care staffing firm in,the ... many baby,boomer nurses may be facing career burn-out. About 46 ...

Cached Medicine News:Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 2 Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 3 Health News:Tug of war in the cells 2 Health News:Tug of war in the cells 3 Health News:Stopping a deadly killer 2 Health News:Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition 2 Health News:Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years 2

Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report Tug of war in the cells Stopping a deadly killer Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition Queensland researchers get the latest tools to fight cancer Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Adenovirus Antibody, IgM Adenovirus Antibodies, IgG & IgM Adenosine Deaminase, RBC Adderall